News | October 17, 2018

Assay.Works And 2bind Partner To Expand Lead Discovery Services

Combining expertise in functional bioassays and molecular interaction studies with High Throughput Screening (HTS) capabilities creates a comprehensive service portfolio supporting Drug Discovery programs.

Assay.Works GmbH (Assay.Works), the experts for bioactivity assay and high-throughput screening (HTS) services and 2bind GmbH (2bind), the specialist CRO for molecular interaction studies and biophysical assays recently announced a partnership significantly expanding the range of lead discovery services offered to clients in the pharmaceutical and biotech industry, and academic organizations.

HTS is a well-established methodology for identifying new lead compounds for drug discovery and chemical biology. Molecular interaction studies are ideally suited to elucidate the molecular mechanism of hit compounds derived from HTS. A combination of HTS, high quality compound libraries, and an understanding of the mechanism of action facilitates the identification and prioritization of unique and tractable starting points for drug discovery programs.

The agreement gives Assay.Works access to 2bind's extensive experience with molecular interaction studies for hit identification, validation, and characterization. Biophysical assay technologies include MicroScale Thermophoresis (MST), nano-scale Differential Scanning Fluorimetry (nanoDSF), Biolayer Interferometry (BLI), and Isothermal Titration Calorimetry (ITC).

2bind's clients will benefit from Assay.Works' broad range of cell-based and biochemical assay capabilities combined with extensive experience in HTS and assay automation. 2bind gains access to 384-well format screening and nanoliter dispensing instrumentation, libraries totaling 150.000 small molecules and 97.000 siRNAs, and a portfolio of assay cell lines.

As part of the agreement, the companies share common laboratory and administrative premises at the BioPark Regensburg. The co-localization facilitates seamless interaction, scientific exchange, and efficiency gains via sharing infrastructure and laboratory equipment.

Dr. Ralf Schwandner, Assay.Works Founder and CEO, commented: "We are excited to partner with 2bind and offer our clients a suite of biophysical assays for hit and lead characterization. The molecular interaction technology perfectly complements our hit-to-lead workflow and the 2bind scientists share our collaborative mindset and approach to client programs. Not to forget, they are a fun team to work with."

Dr. Thomas Schubert, CEO, 2bind added: "You just have to grasp such excellent opportunities!Assay.Works are well-proven experts in assay design, assay development, and large-scale HTS supporting the early stages of drug discovery. Their staff are the highly trained professionals you want to work with. We are glad to now offer our customers access to their HTS and assay development technology!"

For more information, visit https://www.assay.works and https://2bind.com.

SOURCE: Assay.Works GmbH